Sign in

Sam

Director and Equity Research Analyst at Deutsche Bank

Sam Wiseman is a Director and Equity Research Analyst at Deutsche Bank, specializing in European real estate and property companies with coverage including Land Securities Group, British Land, and SEGRO. He has established a strong track record of incisive analysis and actionable recommendations, with notable calls cited among the top analysts for outperformance and consistency, contributing to Deutsche Bank's solid sector ratings and client recognition. Sam began his career at KPMG in audit, then transitioned to real estate equity research roles at Liberum and Canaccord Genuity before joining Deutsche Bank in 2021. He holds ACA chartered accountant certification, possesses UK FCA registration, and is recognized for his detailed sector expertise and analytical rigor.

Sam's questions to Autolus Therapeutics (AUTL) leadership

Question · Q3 2025

Sam, on behalf of James Shin, asked for more details on the data expected at ASH, specifically regarding the pediatric ALL study, the Carlyle study in SLE, and analyses from the FELIX study.

Answer

Dr. Christian Itin, CEO of Autolus Therapeutics, detailed that the pediatric ALL study poster would present phase one experience from approximately 20 patients, including longitudinal safety and response data. The Carlyle study oral presentation would expand on ACR data with additional pharmacodynamic recovery. FELIX study presentations include an oral presentation on product cell phenotypes linked to long-term outcomes and a poster on CAR-T cell persistence at three months as a predictor of outcome.

Ask follow-up questions

Fintool

Fintool can predict Autolus Therapeutics logo AUTL's earnings beat/miss a week before the call

Let Fintool AI Agent track Sam for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free